Pulse
NIFTY 5024,980.40+0.35%
SENSEX81,720.10+0.28%
NIFTY SHARIAH 254,850.15+0.42%
GOLD 24K (10g)₹75,420+0.38%
SILVER (1kg)₹88,400-0.12%
ACTIVE IPOS8 Open+38% GMP
TCS₹4,124.50+1.18%
INFY₹1,892.40+1.22%
USD/INR₹83.92-0.04%
NIFTY 5024,980.40+0.35%
SENSEX81,720.10+0.28%
NIFTY SHARIAH 254,850.15+0.42%
GOLD 24K (10g)₹75,420+0.38%
SILVER (1kg)₹88,400-0.12%
ACTIVE IPOS8 Open+38% GMP
TCS₹4,124.50+1.18%
INFY₹1,892.40+1.22%
USD/INR₹83.92-0.04%
Albert David Limited

Albert David Limited

NSE: ALBERTDAVD
Drug Manufacturers - Specialty & GenericHealthcareSMALL CAPMCap ₹474.3 Cr
₹831.00₹40.30 (+5.10%)

Live • NSE

Market cap₹474.3 Cr
Enterprise value₹223.3 Cr
P/E TTM21.02
P/B1.21
EPS TTM₹39.53
D/E7.56
Dividend yield0.01%
52W high₹931.85
52W low₹579.90
Price chart(1Y)
1Y Return:+14.53% (+₹105.40)
H: ₹931.85L: ₹678
1W+6.42%
1M-0.89%
3M+19.35%
6M+11.88%
1Y+3.74%
Today at a glance

Day range

₹787.00₹836.95

52 week range

₹579.90₹931.85
Volume4.2K1.00x 20D avg
Free float50.00%+0.20% volume

Albert David Limited closed at INR831.00 (+5.1%) on volume 1x its 20-day average, trading 10.82% below its 52-week high.

Technical analysis
RSI (14)50.7Neutral (30–70)
MACDBEARISHBearish (Below signal)
ATR (14)₹29.95High
SMA 20₹834.68BEARISH
SMA 50₹842.82BEARISH
SMA 100₹773.00BULLISH
SMA 200₹740.20BULLISH
CPR bottom₹795.58
Pivot₹793.95
CPR top₹792.33
What changed recently?

2026-Q1

Q1 FY2026 Financial Results

PAT moved -240.1% QoQ

2026-07-30

DIVIDEND Announced

Dividend - Rs 5 Per Share

2025-07-25

DIVIDEND Announced

Dividend - Rs 5 Per Share

Shariah audit
Methodology: AAOIFI Shariah Standard No. 21
PASS4/4 criteria
Shariah Compliant
CriteriaNumeratorDenominatorValueThresholdStatus
Interest-bearing debt ratio₹29.6 Cr₹474.3 Cr6.24%≤ 33%PASS
Non-halal income ratio–₹333.6 Cr0.00%≤ 5%PASS
Illiquid assets ratio₹518.8 Cr₹519.1 Cr99.94%≥ 20%PASS
Receivables ratio–₹519.1 Cr—≤ 49%PASS
Valuation & sector context
MetricCompanySector
P/E21.0237.00
Forward P/E——
P/B1.215.00
EV/EBITDA—18.00
PEG—1.00
Earnings yield4.802.70
Growth & profitability
RevenuePAT
FY20PAT margin 6.00%
FY23PAT margin 10.60%
FY24PAT margin 20.90%
FY25PAT margin 5.00%
FY26PAT margin -0.40%

Revenue and PAT bars use independent scales to make their year-on-year direction readable.

Revenue CAGR 3Y-0.60%
Revenue CAGR 5Y+0.80%
PAT CAGR 3Y—
PAT CAGR 5Y—
Operating margin8.24%
Net margin6.19%
Financial health & cash flow
Net debt₹29.3 CrModerate
Interest coverage-1.60xEBIT / interest
CFO / PAT0.18x3Y average
Net debt / EBITDA—Leverage
Operating cash flow₹-765.9 Lakh
Capital expenditure–
Free cash flow₹-3677.0 Lakh
Financial statements

Complete reported financial history · Values use the company's reporting currency

Hover over the chart for exact reported values. Percentage lines use the right-hand axis.

Fundamental scorecard
Overall63/100
Valuation60/100
Profitability50/100
Financial health80/100

A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.

Strengths, risks & investment thesis

Strengths

Low Debt Profile: Debt-to-Equity is comfortable at 0.08x

Risks

Subject to cyclical raw material and macro industry pressures

Bull case

Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.

Bear case

Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.

Flip condition

Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.

Shareholding pattern
Quarterly ownership historyLatest valid period · December 2025

Ownership distribution

Dec 2025Latest holding

Category trends

Hover over a period for exact holdings

70%47%23%0%Sept 2024Dec 2024Jun 2025Sept 2025Dec 2025
2.23%Institutional holding
35.52%Public holding
5Periods available
0.00%Promoter pledged
13.56KShareholders
Corporate Action

Complete dividend, bonus, split, rights and other action history

Record dateCorporate actionInformationAnnouncement dateEx-date
30 Jul 2026Dividend₹5.00 / share—30 Jul 2026
25 Jul 2025Dividend₹5.00 / share—25 Jul 2025
02 Aug 2024Dividend₹11.50 / share—02 Aug 2024
—Annual General MeetingAnnual General Meeting—02 Aug 2024
03 Aug 2023Dividend₹9.00 / share—03 Aug 2023
—Annual General MeetingAnnual General Meeting—03 Aug 2023
—Dividend₹9.00 / share—01 Aug 2022
07 Sept 2021Dividend₹6.00 / share—06 Sept 2021
—Annual General MeetingAnnual General Meeting—06 Sept 2021
—Annual General MeetingAnnual General Meeting—16 Sept 2020
16 Mar 2020Dividend₹7.00 / share—13 Mar 2020
—Dividend₹6.00 / share—01 Aug 2019
—Dividend₹5.50 / share—24 Aug 2018
—Dividend₹5.50 / share—01 Sept 2017
—Annual General MeetingAnnual General Meeting—01 Sept 2016
Delivery participation

Traded volume and delivery percentage across the latest 20 sessions

Average delivery (20D)69.88%+9.25% latest vs average
Highest delivery82.35%on 01 Oct
Average volume (20D)4.2KTrading-session average
Conviction trendStrengthening+9.25% latest reading
Traded volumeDelivery %
Peer comparison

Compare valuation, latest quarterly performance and year-on-year growth

8 companies
Company nameMarket cap ₹ CrP/E ratioDividend yield %Quarterly sales ₹ CrProfit after tax ₹ CrSales growth %Profit growth %
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries LimitedSUNPHARMA
Open analysis
₹4.22L34.900.91%₹15,300.00₹2,901.00+10.46%+26.52%
Divi's Laboratories Limited
Divi's Laboratories LimitedDIVISLAB
Open analysis
₹2.43L82.970.33%₹3,080.00₹902.00+27.80%+65.50%
Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals LimitedTORNTPHARM
Open analysis
₹1.73L72.830.83%₹4,128.00₹389.00+41.90%-21.89%
Apollo Hospitals Enterprise Limited
Apollo Hospitals Enterprise LimitedAPOLLOHOSP
Open analysis
₹1.13L54.320.25%₹7,044.00₹610.00+20.58%+38.32%
Zydus Lifesciences Limited
Zydus Lifesciences LimitedZYDUSLIFE
Open analysis
₹1.12L25.030.09%₹8,017.00₹990.00+21.95%-34.91%
LENSKART SOLUTIONS LTD
LENSKART SOLUTIONS LTDLENSKART
Open analysis
₹1.12L174.730.00%₹2,714.00₹228.00+43.29%+273.77%
Laurus Labs Limited
Laurus Labs LimitedLAURUSLABS
Open analysis
₹1.11L101.830.12%₹2,026.31₹367.60+29.10%+125.49%
Cipla Limited
Cipla LimitedCIPLA
Open analysis
₹1.07L31.780.98%₹7,119.00₹786.00+2.33%-39.16%
About Albert David Limited
Albert David Limited

Incorporated in 1938, Albert David Ltd is in the business of manufacturing pharmaceutical products[1]

IndiaHealthcare

Questions investors ask
Is Albert David Limited Shariah compliant?

Albert David Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (6.24%) complies with AAOIFI threshold (≤ 33%).

What is Albert David Limited's current valuation relative to peers?

Albert David Limited trades at a P/E of 21.0x compared to the sector median of 37x, and a Price-to-Book of 1.2x.

Is the company financially healthy?

The company has a Debt-to-Equity ratio of 0.08x. Interest coverage is -1.6x.

What are the historical revenue and profit growth rates?

Over the past 5 years, revenue compounded at 0.8% while net profit growth averaged consistent levels.

Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.

Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.